Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

BACKGROUND: Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient models and preliminary clinical activity in BRCA1/2 breast cancer. PATIENTS AND METHODS: This phase II basket multitumor trial (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Boni, V., Pistilli, B., Braña, I., Shapiro, G.I., Trigo, J., Moreno, V., Castellano, D., Fernández, C., Kahatt, C., Alfaro, V., Siguero, M., Zeaiter, A., Longo, F., Zaman, K., Antón, A., Paredes, A., Huidobro, G., Subbiah, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588879/
https://www.ncbi.nlm.nih.gov/pubmed/36037567
http://dx.doi.org/10.1016/j.esmoop.2022.100571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588879/
https://www.ncbi.nlm.nih.gov/pubmed/36037567
http://dx.doi.org/10.1016/j.esmoop.2022.100571

Ejemplares similares